Novadaq Announces NASDAQ Listing

TORONTO, ONTARIO, Mar 01, 2012 (MARKETWIRE via COMTEX) —
Novadaq(R) Technologies Inc.


/quotes/zigman/34261 CA:NDQ
+0.36%



, a developer
of real-time imaging systems for use in the operating room, today
announced that its common shares have been approved for listing on
the NASDAQ Global Market (NASDAQ) under the ticker symbol “NVDQ”.
Novadaq expects that its shares will begin trading on the NASDAQ
exchange today, March 1, 2012. Novadaq will retain its listing on the
Toronto Stock Exchange under the ticker symbol “NDQ”.

“The United States represents the largest market opportunity for
Novadaq’s products and as the awareness for SPY Imaging has grown,
many in the U.S. have expressed interest in investing in our
Company,” said Dr. Arun Menawat, Novadaq’s President and CEO. “We are
pleased to now be listed on the NASDAQ stock market, so we may better
serve the U.S. investment community.”

In connection with its application to list on the NASDAQ, Novadaq
filed a registration statement on Form 40-F with the United States
Securities and Exchange Commission. The Form 40-F includes all of the
Company’s public disclosure for 2011 including restated Fiscal 2011
quarterly financial statements, the effect of which was previously
disclosed in the Company’s Annual 2011 Management Discussion
Analysis. The Form 40-F is available at
www.sec.gov .

About Novadaq Technologies Inc.

Novadaq primarily develops, manufactures and markets real-time
fluorescence imaging products that are designed for use by surgeons
in the operating room and other clinical settings where open,
minimally invasive or interventional surgical procedures are
performed. The Company’s SPY(R) Imaging core technology enables
surgeons to visualize blood flow in vessels, co-joined vessels and
micro-vessels, and to assess the quality of blood perfusion in
tissue, without exposing the patient to radiation. More than 50
peer-reviewed publications demonstrate that the use of SPY Imaging
during complex surgery leads to fewer post-operative complications
and lower hospital costs. The SPY Imaging System is United States
Food and Drug Administration (“FDA”) 510(k) cleared for use during a
variety of open surgical applications. The endoscopic version of SPY,
which is branded PINPOINT(TM), combines the capabilities of SPY
Imaging with high definition (“HD”) visible light visualization
offered by conventional endoscopes. The majority of Novadaq’s current
revenues come from alliances formed with leading companies in
relevant markets in which SPY technology has been demonstrated to
improve clinical outcomes in open, minimally invasive and robotic
surgery applications. Novadaq’s first alliance integrates SPY Imaging
into the 3-D HD imaging capabilities of the da Vinci(R) Surgical
Robotic System offered by Intuitive Surgical(R), Inc. The integrated
system received FDA 510(k) clearance in February 2011. In September
2010, Novadaq entered into an exclusive North American sales and
marketing alliance with LifeCell(TM) Corporation, for SPY in open
plastic and reconstructive, gastrointestinal and head and neck
surgeries. In November 30, 2011, Novadaq signed exclusive, multi-year
sales and marketing agreements with Kinetic Concepts, Inc., for wound
care applications and extended its agreement with LifeCell for the
commercialization of the SPY System into vascular surgery. In
addition, the SPY Imaging System for cardiac applications is marketed
directly, whereas the CO2 Heart Laser(TM) for TMR is distributed by
MAQUET Cardiovascular. For more information, please visit the
Company’s website at
http://www.novadaq.com .

Forward-Looking Statements

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. All
forward-looking statements are based on Novadaq’s current beliefs as
well as assumptions made by and information currently available to
Novadaq and relate to, among other things, the Company’s strategy,
strategic goals, research and development activities, research and
clinical testing outcomes, taxes, capital expenditures, future
operations, future financial position, future revenues/results,
projected costs, prospects and plans and objectives of management.

Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks
and uncertainties identified by Novadaq in its public securities
filings available at
www.sedar.com , actual events may differ
materially from current expectations. Novadaq disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

Note: LifeCell(TM) Corporation is a business unit and trademark of
Kinetic Concepts, Inc. Intuitive Surgical and da Vinci are registered
trademarks of Intuitive Surgical.



        
        Contacts:
        Novadaq Technologies Inc.
        David C. Martin
        Vice President, Corporate Development and Investor Relations
        905-629-3822 ext: 218
        dmartin@novadaq.com
 
www.novadaq.com            
        
        


SOURCE: Novadaq Technologies Inc.



        mailto:dmartin@novadaq.com
 
Home

Copyright 2012 Marketwire, Inc., All rights reserved.

/quotes/zigman/34261



Add NDQ to portfolio

CA:NDQ